ArticleFrontiers in neurology2025
The journey to diagnosis for patients with CIDP: results from a real-world international survey.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare autoimmune disorder affecting the peripheral nerves, typically characterized by muscle weakness and sensory deficits. This study seeks to describe CIDP patients' journey to diagnosis alongside factors influencing misdiagnosis and time to diagnosis. Methods: We analyzed demographics and diagnostic data reported by neurologists and their patients in Adelphi's CIDP Disease Specific Programme™. This digital, multinational real-world survey was held in the UK, France, Germany, Italy and Spain between September 2022 and April 2023 ( Results: Mean (SD) age was 54.0 (12.4) years; 62% of patients were male. Half of the patients reported at least one comorbidity, with anxiety, depression and diabetes being the most common. The mean (SD) number of diagnostic procedures undergone per patient was 19.6 (9.4). An electromyogram and nerve conduction study (98%), complete blood count (82%) and administration of anti-ganglioside antibodies (78%) were carried out most frequently. Most patients had been diagnosed with typical CIDP (68%) and 37% had been misdiagnosed at least once. The most common misdiagnosis was Guillain-Barré syndrome, in 37% of cases. No significant associations were found between misdiagnosis and the variables sex, disease severity at symptom onset, age category, BMI or CIDP subtype. The median (Q1 - Q3) time between symptom onset and diagnosis was 7.0 (3.2-13.0) months. A multiple linear analysis on the log-transform of the time to diagnosis indicated that patients with a long time to diagnosis more often presented with mild symptoms at onset, had variant CIDP and had been misdiagnosed. Conclusion: Median time to diagnosis for CIDP patients was 7 months; over a third had at some point been misdiagnosed. Mild symptoms, having variant CIDP and having been misdiagnosed were associated with longer time to diagnosis. Further research into the causes of diagnostic delay and the impact of late diagnosis and treatment is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.